ReviewBiomarker insights2023
The Latest Developments in Using Proteomic Biomarkers from Urine and Serum for Non-Invasive Disease Diagnosis and Prognosis.
Review in Biomarker insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Peptidomic Profiling Reveals Extracellular Matrix Remodeling Signatures Discriminative of Multiple Myeloma.Proteomics · 2026Article
- Endometriosis: Epidemiology, Risk Factors, Molecular Mechanisms, Diagnosis, and Management.MedComm · 2026Review
- Artificial intelligence-based models for colorectal cancer diagnosis using laboratory tests: an exploratory retrospective case-control study.Translational cancer research · 2026Article
- Inflammatory Signatures and Biomarkers: The Renal-Vesical Axis in Alzheimer Progression.International neurourology journal · 2026Article
- Proteomics research in aging: a bibliometric and visualized analysis of evolution and emerging trends (1998-2024 and early 2025).Biogerontology · 2025Article
- The Urinary Proteome Differs with the Presence and Type of Breast Cancer.Journal of proteome research · 2025Article
- Urinary Multi-Omics Profiling Reveals Systemic Molecular Alterations in Progressive External Ophthalmoplegia.International journal of molecular sciences · 2025Article
- Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.ACS nano · 2025Review
- Diagnostic value of lnc-RNAs TINCR, GC1 and AFAP1-AS1 in gastric cancer differentiation from healthy people.Biomarkers in medicine · 2025Article
- Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and Challenges.Cureus · 2025Review
- Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.Breast cancer research : BCR · 2025Article
- Urinary Proteomic Shifts over Time and Their Associations with eGFR Decline in Chronic Kidney Disease.Biomolecules · 2025Article
- Proteomic characteristics of bronchoalveolar lavage fluid in children with mild and severeFrontiers in microbiology · 2025Article
- 3D Simulation-Driven Design of a Microfluidic Immunosensor for Real-Time Monitoring of Sweat Biomarkers.Micromachines · 2024Article
- Investigating and Annotating the Human Peptidome Profile from Urine under Normal Physiological Conditions.Proteomes · 2024Article
- Candidate protein biomarkers in chronic kidney disease: a proteomics study.Scientific reports · 2024Article
- Article
- The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins.International journal of molecular sciences · 2024Review
- Recent progress in mass spectrometry-based urinary proteomics.Clinical proteomics · 2024Review
- Proteomics analysis reveals age-related proteins in the urine of chronic kidney disease patients.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to diagnostic improvements, medical diagnostics is demanding non-invasive or minimally invasive methods. Non-invasively obtained body fluids (eg., Urine, serum) can replace cerebral fluid, amniotic fluid, synovial fluid, bronchoalveolar lavage fluid, and others for diagnostic reasons. Many illnesses are induced by perturbations of cellular signaling pathways and associated pathway networks as a result of genetic abnormalities. These disturbances are represented by a shift in the protein composition of the fluids surrounding the tissues and organs that is, tissue interstitial fluid (TIF). These variant proteins may serve as diagnostic "signatures" for a variety of disorders. This review provides a concise summary of urine and serum biomarkers that may be used for the diagnosis and prognosis of a variety of disorders, including cancer, brain diseases, kidney diseases, and other system diseases. The studies reviewed in this article suggest that serum and urine biomarkers of various illnesses may be therapeutically useful for future diagnostics. Correct illness management is crucial for disease prognosis, hence non-invasive serum and urine biomarkers have been extensively studied for diagnosis, subclassification, monitoring disease activity, and predicting treatment results and consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.